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The dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), exerts powerful
therapeutic effects but eventually generates L-DOPA-induced dyskinesia (LID) in patients
with Parkinson’s disease (PD). LID has a close link with deregulation of striatal
dopamine/cAMP signaling, which is integrated by medium spiny neurons (MSNs).
Olfactory type G-protein α subunit (Gαolf), a stimulatory GTP-binding protein encoded by
the GNAL gene, is highly concentrated in the striatum, where it positively couples with
dopamine D1 (D1R) receptor and adenosine A2A receptor (A2AR) to increase intracellular
cAMP levels in MSNs. In the striatum, D1Rs are mainly expressed in the MSNs that form
the striatonigral pathway, while D2Rs and A2ARs are expressed in the MSNs that form
the striatopallidal pathway. Here, we examined the association between striatal Gαolf
protein levels and the development of LID. We used a hemi-parkinsonian mouse model
with nigrostriatal lesions induced by 6-hydroxydopamine (6-OHDA). Using quantitative
immunohistochemistry (IHC) and a dual-antigen recognition in situ proximity ligation
assay (PLA), we here found that in the dopamine-depleted striatum, there appeared
increased and decreased levels of Gαolf protein in striatonigral and striatopallidal MSNs,
respectively, after a daily pulsatile administration of L-DOPA. This leads to increased
responsiveness to dopamine stimulation in both striatonigral and striatopallidal MSNs.
Because Gαolf protein levels serve as a determinant of cAMP signal-dependent activity
in striatal MSNs, we suggest that L-DOPA-induced changes in striatal Gαolf levels in the
dopamine-depleted striatum could be a key event in generating LID.
Keywords: olfactory type G-protein α subunit, dopamine, striatum, Parkinson’s disease, L-DOPA-induced
dyskinesia
INTRODUCTION
Human pathology has shown that Parkinson’s disease (PD) results from dopamine deficiency
in the neostriatum, particularly in the putamen, due to degenerative loss of nigrostriatal
dopaminergic cells (Kish et al., 1988; Goto et al., 1989). Treatments with the dopamine
precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), remain the gold standard of drug
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therapy for PD. However, after prolonged and pulsatile exposure
to L-DOPA, PD patients eventually develop L-DOPA-induced
dyskinesia (LID; Jenner, 2008; Calabresi et al., 2010; Huot et al.,
2013). LID is an adverse event that occurs in more than 50% of
patients after 5–10 years (Ahlskog and Muenter, 2001; Rascol
et al., 2006). Importantly, once LID has been established, its
severity increases unless dopaminergic drug dosage is reduced
(Brotchie, 2005). It is known that the severity of loss of nigral
dopaminergic cells represents the most important factor that
determines the severity of LID (Guridi et al., 2012; Bastide et al.,
2015). However, the nature of the cellular and molecular key
events that lead to a progressive increase in responsiveness to
dopaminergic stimulation in LID remains unclear.
LID is closely linked with pathological changes in
dopaminergic transmissions in the striatum (Bastide et al.,
2015; Calabresi et al., 2016). Dopamine receptors are categorized
into two subclasses, D1- and D2-type receptors, based on their
functional properties to stimulate and inhibit the adenylyl
cyclase-mediated cAMP production via specific targeting of
G-proteins, respectively (Kebabian and Calne, 1979; Missale
et al., 1998). There is a large body of evidence showing that
increased activity of dopamine D1-receptors (D1Rs) is necessary
for LID development (Westin et al., 2007; Darmopil et al.,
2009; Alcacer et al., 2012). D1R activation leads to multiple
molecular events, such as the induction of immediate early
genes (Cenci et al., 1999; Gerfen et al., 2002; Darmopil et al.,
2009) and the activation of extracellular signal-regulated
kinases (Gerfen et al., 2002; Pavón et al., 2006; Santini et al.,
2007, 2009; Westin et al., 2007; Rylander et al., 2009; Ding
et al., 2011). Striatal dopamine/cAMP signaling is integrated
by medium spiny neurons (MSNs), which are the principal
neurons of the striatum (Graybiel, 2008; Kreitzer, 2009; Gerfen
and Surmeier, 2011). MSNs can be divided into two distinct
subpopulations on the basis of their axon projections, which
form the ‘‘direct’’ striatonigral and ‘‘indirect’’ striatopallidal
pathways (Crittenden and Graybiel, 2011; Gerfen and Surmeier,
2011). Interestingly, anatomical evidence has shown that
D1Rs and D2Rs are mainly expressed in striatonigral and
striatopallidal MSNs, respectively. Moreover, adenosine
A2A receptor (A2AR), a prototypical Gs-coupled receptor,
is enriched in the striatum, where it is mainly expressed in
striatopallidal, but not striatonigral, MSNs (Schiffmann et al.,
1991; Svenningsson et al., 1999; Schwarzschild et al., 2006; Fuxe
et al., 2007).
Olfactory type G-protein α subunit (Gαolf), the stimulatory
G-protein encoded by the GNAL gene, is highly concentrated
in the striatum, where it positively couples with D1R and A2AR
to activate adenylyl cyclase and, thereby, increase intracellular
cAMP levels in MSNs (Hervé, 2011). As Gαolf represents
the rate-limiting factor for the D1R- and A2AR-dependent
cAMP production (Kull et al., 2000; Corvol et al., 2001),
Gαolf protein level serves as a determinant of cAMP signal-
dependent activity in both D1R-expressing striatonigral MSNs
(D1-cells) and D2R-expressing striatopallidal MSNs (D2-cells).
D1R/Gαolf-mediated increases in intracellular cAMP levels
facilitate D1-cell activity (Hervé, 2011), while the elevation of
intracellular cAMP levels via A2AR/Gαolf activation functionally
opposes the actions of D2Rs on D2-cells (Schwarzschild et al.,
2006; Fuxe et al., 2007). It is also known that Gαolf protein
levels in striatal MSNs are regulated by posttranslational
usage-dependent mechanism through the activation of D1Rs
(Hervé et al., 2001; Corvol et al., 2004, 2007; Alcacer et al.,
2012; Ruiz-DeDiego et al., 2015) and A2ARs (Hervé et al.,
2001).
The aim of this study was to clarify the association of striatal
Gαolf protein levels with LID development. For this purpose, we
used a hemi-parkinsonian mouse model with nigrostriatal lesion
induced by 6-hydroxydopamine (6-OHDA). Using quantitative
immunohistochemistry (IHC) and a highly-sensitive in situ
proximity ligation assay (PLA), we show that in the 6-OHDA-
lesioned striatum, daily pulsatile injections of L-DOPA might
cause changes in Gαolf levels in not only D1-cells but also
D2-cells, and lead to elevated responsiveness to dopamine
stimulation in both D1-cells and D2-cells. This novel finding
suggests that L-DOPA-induced changes in striatal Gαolf levels in




All experimental procedures involving the use of animals and
the analysis of brain anatomy were approved by the Institutional
Care and Use Committees of Tokushima University, Japan.
Adult male C57BL/6 mice aged 8–9 weeks were purchased
from Nihon SLC Co. (Shizuoka, Japan). Mice were housed in a
controlled environment (23 ± 1◦C, 50 ± 5% of humidity) with
12 h light/dark cycle. Mice were allowed to take food and tap
water ad libitum.
Stereotaxic Injection of 6-OHDA
Mice were anesthetized with isoflurane (Sigma-Aldrich, St. Louis,
MO, USA) and were mounted on a stereotaxic frame (Narishige,
Tokyo, Japan). Each mouse received a stereotaxic injection of
6-OHDA-HCl (8.2 µg) dissolved in 4 µl of saline containing
0.02% ascorbic acid. Two 2-µl injections were administered
into the striatum at a rate of 1 µl/min. The needle was left
in place for 5 min to allow diffusion away from the injection
site. The stereotaxic coordinates according to the mouse brain
atlas (Paxinos and Franklin, 2001) were anterior-posterior, +0.5;
medial-lateral, +2.4; and dorsal-ventral, −4.0 and −3.0. Mice
were allowed to recover for 3 weeks and then apomorphine
(Sigma-Aldrich; 0.5 mg/kg)-induced rotation behavior was
studied over the course of 60 min. Mice with contralateral
rotations (>7 times/min) were chosen and used for further
studies.
L-DOPA Treatments
Three weeks after the 6-OHDA-lesioning, mice received
intraperitoneal injections of L-DOPA (Sigma-Aldrich; 20 mg/kg
of free base) dissolved in 0.9% saline and intraperitoneal
injections of benserazide-HCl (Sigma-Aldrich; 12 mg/kg)
dissolved in 0.9% saline 20 min before daily administration of
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L-DOPA over 10 days. On day 11, themice underwent behavioral
studies and were then sacrificed for histological studies.
Assessment of Abnormal Involuntary
Movements (AIMs)
AIM scoring was performed according to previous reports (Cenci
et al., 1998; Pavón et al., 2006; Santini et al., 2007). AIM scores
were obtained after the last injection of L-DOPA for 1 min every
10 min over a period of 140 min. For the evaluation, each mouse
was placed in a glass cylinder (diameter of 12 cm). Purposeless
movements were classified on the basis of their topographic
distribution. The following four subtypes of AIMs were present:
locomotive (tight contralateral turns), axial (twisted posturing
of the neck and upper body toward the contralateral side),
forelimb (jerky movements of the contralateral forelimb, and/or
grabbing movement of the contralateral paw), and orolingual
(jaw movements and tongue protrusion toward the contralateral
side). Each subtype was scored as follows; 0, absent; 1, occasional;
2, frequent; 3, continuous; 4, continuous, not interrupted by
sensory stimuli.
Tissue Preparations
Immediately after the last AIM scoring, the mice were
intraperitoneally administered a lethal dose of pentobarbital
(Sigma-Aldrich). They were then transcardially perfused with
0.01 M phosphate-buffered saline (PBS) at pH 7.2, followed by
cold 4% paraformaldehyde in 0.1 M phosphate buffer at pH
7.2. The brains were removed, post-fixed overnight in the same
fixative at 4◦C, and stored in a 10–30% sucrose gradient in 0.1 M
phosphate buffer at 4◦C for cryoprotection. Sixteen-micrometre-
thick sections were cut on a cryostat and stored in PBS containing
0.05% NaN3 until use.
IHC
Immunostaining was performed on free-floating sections using
the tyramide signal amplification (TSA) method, as in our
previous report (Okita et al., 2012). After blocking endogenous
peroxidase activity, the sections were incubated in PBS
containing 3% bovine serum albumin (BSA) for 60 min. They
were then incubated with antibodies against one of the following
(diluted in PBS-BSA): Gαolf (rabbit polyclonal, 1:5000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), tyrosine hydroxylase
(TH, rabbit polyclonal, 1:100,000) (Sato et al., 2008;Morigaki and
Goto, 2016), D1R (mousemonoclonal, 1:5000; Novus Biologicals,
Littleton, CO, USA), A2AR (mouse monoclonal, 1:5000; Santa
Cruz Biotechnology), D2R (rabbit polyclonal, 1:2000; Merck
Millipore, Billerica, MA, USA) or c-Fos (rabbit polyclonal,
1:50,000; Oncogene Science, Cambridge, MA, USA) for 18 h.
The bound antibodies were detected using the Histofine Simple
Stain Kit (Nichirei, Tokyo, Japan) and the TSA-system with
Cyanine3 or Fluorescein (Perkin Elmer, Shelton, CT, USA). For
double immunofluorescence staining, the sections stained for
Gαolf using Cyanine3 were incubated in 0.1 M glycine-HCl (pH
2.2) at room temperature for 30 min. After rinsing in PBS for 1 h,
the sections were then incubated overnight at room temperature
in PBS containing 3% BSA and a rabbit polyclonal antibody
against the µ-opioid receptor (MOR; 1:20,000; Millipore,
Billerica, MA, USA), a mouse monoclonal antibody against D1R
(1:5000; Novus Biologicals), or a mouse monoclonal antibody
against A2AR (1:5000; Santa Cruz Biotechnology). The bound
antibodies were detected using the Histofine Simple Stain Kit
(Nichirei) and the TSA-system with Fluorescein (Perkin Elmer).
Dual-Antigen Recognition In Situ PLA
Dual-antigen recognition PLA experiments were conducted
using the Brightfield Duolink PLA kit reagents (Sigma-Aldrich)
according to the manufacturer’s recommendations with some
modifications. Briefly, after blocking endogenous peroxidases
in PBS containing 0.1% H2O2 for 30 min, the free-floating
sections were incubated in PBS containing 3% normal goat serum
for 60 min. They were then incubated in PBS containing 3%
normal goat serum and a rabbit polyclonal antibody against Gαolf
(1:500; Santa Cruz Biotechnology) in combination with a mouse
monoclonal antibody against D1R (1:500; Novus Biologicals) or
a mouse monoclonal antibody against A2AR (1:500; Santa Cruz
Biotechnology) for 18 h at room temperature. After subsequent
secondary labeling with rabbit PLA minus and mouse PLA plus
probes, we used the Brightfield Duolink Detection reagents for
ligation and amplification and label probe binding according to
the manufacturer’s instructions. For final signal visualization,
we used the TSA-system with Cyanine3 (Perkin Elmer). After
mounting on slides, the stained sections were counterstained
with hematoxylin and were cover-slipped using 10% glycerol
in PBS.
Digital Imaging and Morphometry
Digital microscopy images were captured using an Olympus
BX51 microscope (Olympus, Tokyo, Japan) equipped with a
DP40 digital camera (Olympus). They were imported into
Adobe Photoshop CS4 and processed digitally. We adjusted
contrast, brightness, and color balance. Using an image analyzer
(MetaMorph, Molecular Device, Tokyo, Japan), we measured
the optical densities of immunoreactive products and PLA
signals in the striatum, which were represented by gray levels
on non-colored digital images (Sato et al., 2008; Goto et al.,
2013; Morigaki and Goto, 2015). Using the same protocol
described above, we also measured optical densities of Gαolf-
immunoreactive products in the striosome and matrix subfields
in the striatal sections double-stained for Gαolf and MOR. We
also counted the numbers of neuronal nuclei positive for c-Fos in
a 0.5 mm × 0.5 mm field in the striatum and globus pallidus, as
in our previous report (Tanabe et al., 2014). These morphometric
analyses were carried out in a blind manner.
Statistical Analysis
All experimental values are expressed as means ± SEM. For
two-group comparisons, we used a paired two-tailed t-test.
Multiple comparisons were analyzed using one-way or two-way
analysis of variance (ANOVA), followed by Bonferroni’s
post hoc tests for pair wise comparisons. Statistical analyses were
performed using Stat View 5.0 (SAS Institute, Cary, NC, USA)
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 February 2017 | Volume 11 | Article 26
Morigaki et al. Striatal Gαolf Levels in L-DOPA-Induced Dyskinesia
software. P-values of less than 0.05 were considered statistically
significant.
RESULTS
Generation of a Mouse Model with LID
To model the generation of AIMs in PD following repeated
L-DOPA treatments, we employed a well-established PD mouse
model in which mice first received unilateral injection of
6-OHDA into the striatum (Santini et al., 2007). After 3 weeks
of recovery and an apomorphine test, the mice were subjected
to L-DOPA treatment for 10 days according to standardized
protocols (Figure 1A). In this study, 6-OHDA-lesioned mice
administered daily injections of benserazide-HCl (12 mg/kg)
alone for 10 days were designated as ‘‘PD’’ models. Six-
OHDA-lesioned mice that received daily injections of L-DOPA
(20 mg/kg) and benserazide-HCl (12 mg/kg) for 10 days and
finally exhibited LIDs with total AIM scores of more than 20 were
designated as ‘‘PD with Dyskinesia (PD-D)’’ models. Among
6-OHDA-lesionedmice that received daily injections of L-DOPA
(n = 28), 25 mice (∼90%) were grouped into the PD-D model.
Mice that received no drug treatment, except for anesthetic
drugs, were used as ‘‘naïve controls’’.
In both PD and PD-D mice, IHC with anti-TH antibody
revealed a severe loss of nigral dopaminergic cells (Figure 1B)
and striatal dopaminergic afferents (Figure 1C) on the
side of the 6-OHDA injection. Quantitative measurements
(Figure 1D) revealed a greater-than-90% reduction in TH
labeling in the dorsolateral (DL) striatum on the lesioned
side when compared to the non-lesioned side (lesion side,
3.9 ± 2.1; non-lesion side, 56.5 ± 8.9; means ± SEM;
n = 10; two-tailed t-test, P < 0.01). Figure 1E shows the
time course of changes in LIDs as determined by AIM scoring
in PD-D mice. AIMs were maximal 40 min after L-DOPA
administration, declined after 70 min, and almost disappeared
after 120 min.
Regional and Cellular Localization of Gαolf
in the Normal Mouse Striatum
Figure 2A depicts the known distributional patterns of Gαolf,
D1R, and A2AR in a simplified basal ganglia circuit diagram. Note
that Gαolf is mainly localized with D1R in the D1-cells that form
the striatonigral pathway, while it is localized with A2AR in the
D2-cells that form the striatopallidal pathway. Using IHC, we
reappraized the localization profile of Gαolf immunoreactivity
(IR) in the mouse striatum. Low-magnification microscopic
images show strong Gαolf labeling in the striatum (Figure 2B),
particularly in the DL region (Figure 2B’, arrows). As in our
previous report (Sako et al., 2010), Gαolf IR was differentially
concentrated in the different striatal compartments, with
heightened Gαolf labeling in the striosomes relative to the matrix
(Figures 2C,D). Optical density measurements (Figure 2E)
also revealed that Gαolf IR in the striosomes was significantly
higher than that in the matrix (striosomes, 39.8 ± 5.0; matrix,
FIGURE 1 | Generation of hemi-parkinsonian mice with L-DOPA-induced dyskinesia (LID). (A) Timeline of treatments and observations (also see “Materials
and Methods” Section). (B,C) Representative photomicrographs of the substantia nigra (B, arrows) and striatum (C, asterisks) stained for tyrosine hydroxylase (TH)
on the non-lesioned (Non-lesion) and lesioned (Lesion) sides in mice with 6-hydroxydopamine (6-OHDA)-induced lesions. (D) Quantification of mean TH staining
intensity in the dorsolateral (DL) striatum on the non-lesioned (Non-lesion) and lesioned (Lesion) sides. Data are means ± SEM (n = 10). Paired two-tailed t test:
∗∗P < 0.01 vs. Non-lesion. (E) Time course of total abnormal involuntary movements (AIMs) scored every 10 min over a period of 140 min after the last L-DOPA
administration. Data are means ± SEM at the each time point (n = 10 per group). Scale bars: (B) = 1 mm; (C) = 2 mm.
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FIGURE 2 | Striatal localization of Gαolf protein in normal mice. (A) Localization pattern of Gαolf in a simplified basal ganglia circuit. Note that Gαolf is
colocalized with D1R in striatonigral medium spiny neurons (MSNs; D1-cells), but with adenosine A2A receptor (A2AR) in D2R-expressing striatopallidal MSNs
(D2-cells). The striatonigral and striatopallidal pathways arising from the striosome are omitted in this scheme. Abbreviations: SNc, substantia nigra pars compacta;
VTA, ventral tegmental area. (B,B’) Multiple frontal sections of the striatum stained for Gαolf from naïve control mice (B) and their graded color-converted images (B’).
Note that Gαolf immunoreactivity (IR) is highly concentrated in the DL portion of the striatum (arrows). (C) Representative photomicrograph of the striatum stained for
Gαolf. Asterisk indicates an example of the striosomes. (D,D’) Representative photomicrographs of the DL striatum double-stained for Gαolf (D) and µ-opioid
receptor (MOR) (D’). Corresponding striosomes are indicated by arrows. (E) Quantification of mean Gαolf staining intensity in the striosome and matrix compartments
in the DL striatum. Data are means ± SEM (n = 10). Paired two-tailed Student’s t test: ∗∗P < 0.01, Striosome vs. Matrix. (F) Representative photomicrographs of the
DL striatum stained for Gαolf with DAPI (4,6-diamidino-2-phenylindole)-staining. Tiny dots positive for Gαolf (inset) are shown. (G,H) Representative photomicrographs
of neurons double-stained for Gαolf and D1R (G) or A2AR (H) in the DL striatum. (I,J) Representative photomicrographs of the DL striatum stained with the dual
recognition in situ proximity ligation assay (PLA) for Gαolf-D1R (I) or Gαolf-A2AR (J). Tiny dots showing the PLA signals for Gαolf-D1R (I) or Gαolf-A2AR (J) are
abundant. Microscopic images at higher magnifications are shown in the insets (arrows) in (I,J). Scale bars: (B,C) = 1 mm; (D,D’) = 200 µm: (F–J) = 10 µm; inset in
(F) = 5 µm; insets in (I,J) = 2.5 µm.
23.5 ± 6.0; means ± SEM; n = 10; two-tailed t-test, P < 0.01).
Microscopic images with high magnification show numerous
tiny dots of Gαolf IR densely distributed in the DL striatum
(Figures 2F–H). In the double-labeling study, Gαolf-positive dots
were frequently localized in MSNs labeled for D1R (Figure 2G)
or A2AR (Figure 2H). Using dual-antigen recognition in situ
PLA, which indicates that two proteins are in close proximity
(Söderberg et al., 2006), we also found that dot signals indicating
the presence of Gαolf protein in close proximity to D1R protein
(D1R-Gαolf; Figure 2I) or A2AR protein (A2AR-Gαolf; Figure 2J)
were abundantly distributed in the DL striatum.
Dopaminergic Regulation of Striatal Gαolf
Protein Levels
To examine the dopaminergic regulation of Gαolf protein
levels in the striatum, we performed a quantitative IHC using
an anti-Gαolf antibody on striatal sections prepared from
naïve control, PD, and PD-D mice. In low-magnification
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FIGURE 3 | Dopaminergic regulation of striatal Gαolf levels. (A,B) Representative low-magnification microscopic images of striatal sections stained for Gαolf
on the non-lesion and lesion sides from 6-OHDA-lesioned mice treated with daily injections of benserazide alone for 10 days (PD model; (A) and 6-OHDA-lesioned
mice that received daily injections of benserazide and L-DOPA for 10 days and exhibited dyskinesia (PD-D model; B). (C–E) Representative higher-magnification
microscopic images of the DL striatum stained for Gαolf from naïve control (C), PD (D) and PD-D (E) mice. (F–H) Optical density quantification of Gαolf IR in the DL
striatum on the non-lesion and lesion sides from PD (n = 15) and PD-D (n = 15) mice. Data are expressed as percentage of naïve control mice (n = 15) and are
means ± SEM. (F) Quantification of Gαolf IR in the DL regions in the striatum. ∗∗∗P < 0.001 vs. naïve controls; ##P < 0.01 vs. PD; two-way analysis of variance
(ANOVA) (F(1,56) = 75.5) followed by Bonferroni’s test. (G) Quantification of Gαolf IR in the striosome subfields in the DL striatum. ∗∗P < 0.01 vs. naïve controls; N.S.
(not significant) vs. PD; two-way ANOVA (F(1,56) = 9.2) followed by Bonferroni’s test. (H) Quantification of Gαolf IR in the matrix subfields in the DL striatum.
∗∗∗P < 0.001 vs. naïve controls; ##P < 0.01 vs. PD; two-way ANOVA (F(1,56) = 89.6) followed by Bonferroni’s test. Scale bars: (A,B) = 2 mm; (C–E) = 100 µm.
microscopic images, PD mice (Figure 3A) showed dramatic
increases in Gαolf IR in the dorsal striatum on the 6-OHDA-
lesioned side when compared to non-lesioned side. In contrast,
PD-D mice (Figure 3B) only had a modest increase in
striatal Gαolf IR on the 6-OHDA-lesioned side relative to
non-lesioned side. Higher-magnification microscopic images
of the DL striatum also show that, when compared to
naïve controls (Figure 3C), there is a marked, but, slight
increase in Gαolf IR in the 6-OHDA-lesioned striatal areas of
PD (Figure 3D) and PD-D (Figure 3E) mice. As indicated
in a previous report (Ruiz-DeDiego et al., 2015), it is
likely that dopamine depletion increases Gαolf IR mainly
in the matrix of the 6-OHDA-lesioned striatum, leading
to a loss of the striosome-predominant pattern of Gαolf
IR expression in PD mice. However, daily treatment with
L-DOPA reverses the lesion-induced increase in Gαolf IR
primarily in the matrix, leading to reappearance of the
striosome-predominant pattern of Gαolf IR expression in PD-D
mice. These visual impressions were confirmed by quantitative
densitometry analyses of the DL striatum (Figures 3F–H),
as follows. We found a significant and marked increase of
101% (P < 0.001, two-way ANOVA) in Gαolf IR levels
in the 6-OHDA-lesioned striatum of PD, when compared
to naïve controls. There was a 67% decrease (P < 0.01,
two-way ANOVA) in Gαolf IR levels in the 6-OHDA-lesioned
striatum of PD-D mice when compared to that of PD
mice (Figure 3F; PD mice: non-lesion, 102 ± 17% and
6-OHDA-lesion, 201± 28%; PD-D mice: non-lesion, 103± 19%
and 6-OHDA-lesion, 134± 16%; % of naïve control mice± SEM;
n = 15).
In the striatal compartments of the DL striatum, we found a
significant increase of 38% (P < 0.01, two-way ANOVA) Gαolf
IR levels in the striosomes of 6-OHDA-lesioned striatum of
PD, when compared to naïve controls. There was no apparent
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difference (P > 0.05, two-way ANOVA) in striosomal levels
of Gαolf IR in the 6-OHDA-lesioned striatum between PD and
PD-D mice (Figure 3G; PD mice: non-lesion, 101 ± 22% and
6-OHDA-lesion, 138± 26%; PD-D mice: non-lesion, 102± 19%
and 6-OHDA-lesion, 122± 20%; % of naïve control mice± SEM;
n = 15). We also found a significant increase of 96% (P < 0.001,
two-way ANOVA) in matrix levels of Gαolf IR in the 6-OHDA-
lesioned striatum of PD mice, when compared to those of
naïve controls. There was a 66% decrease (P < 0.01, two-way
ANOVA) in matrix levels of Gαolf IR in the 6-OHDA-lesioned
striatum of PD-D mice when compared to those of PD mice
(Figure 3H; PD mice: non-lesion, 99 ± 23% and 6-OHDA-
lesion, 196 ± 24%; PD-D mice: non-lesion, 102 ± 12% and
6-OHDA-lesion, 130 ± 22%; % of naïve control mice ± SEM;
n = 15). These findings indicate that dopamine depletion
causes a dramatic increase in Gαolf levels in the DL striatum,
particularly in the matrix. Daily exposure to L-DOPA induces
a down-regulation of this lesion-induced increase in Gαolf
expression.
Dopaminergic Regulation of Striatal
Expression of D1R, A2AR, and D2R
To examine dopaminergic regulation of D1R, A2AR and D2R
expression in the DL striatum, we performed quantitative IHC
on sections prepared from 6-OHDA-lesioned striata of PD and
PD-D mice (Figure 4). We observed no significant changes
(P > 0.05, one-way ANOVA) in the expression levels of D1R
IR in PD or PD-D mice when compared to naïve controls
(Figures 4A,B; PD mice, 101 ± 21%; PD-D mice, 98 ± 17%;
% of naïve control mice ± SEM; n = 15). The expression
levels of A2AR IR in PD and PD-D mice were not significantly
different (P > 0.05, one-way ANOVA) from those in naïve
controls (Figures 4C,D; PD mice, 103 ± 15%; PD-D mice,
FIGURE 4 | Dopaminergic regulation of striatal expression of D1R, A2AR and D2R. (A) Representative photomicrographs of striatal expression of D1R in
normal (naïve controls) and lesioned hemispheres from 6-OHDA-lesioned mice treated with daily injections of benserazide alone for 10 days (PD model), and from
6-OHDA-lesioned mice that received daily injections of benserazide and L-DOPA for 10 days and exhibited dyskinesia (PD-D model). (B) Optical density
quantification of D1R IR in the DL striatum from PD (n = 15) and PD-D (n = 15) mice. Data are expressed as percentage of naïve control mice (n = 15) and are
means ± SEM. No significant changes in striatal levels of D1R IR in PD and PD-D mice were observed when compared to naïve controls; one-way ANOVA
(F(2,42) = 0.0) followed by Bonferroni’s test. (C) Representative photomicrographs of striatal expression of A2AR from naïve control, PD and PD-D mice. (D) Optical
density quantification of A2AR IR in the DL striatum from PD (n = 15) and PD-D (n = 15) mice. Data are expressed as percentage of levels in naïve control mice
(n = 15) and are means ± SEM. No significant changes in striatal levels of A2AR IR in PD and PD-D mice were observed when compared to naïve controls; one-way
ANOVA (F(2,42) = 1.2) followed by Bonferroni’s test. (E) Representative photomicrographs of striatal expression of D2R from naïve control, PD and PD-D mice.
(F) Optical density quantification of D2R IR in the DL striatum from PD (n = 15) and PD-D (n = 15) mice. Data are expressed as percentage of levels in naïve control
mice (n = 15) and are means ± SEM. ∗∗P < 0.01 vs. naïve controls; one-way ANOVA (F(2,42) = 16.9) followed by Bonferroni’s test. Scale bars: (A,C,E) = 1 mm.
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118 ± 13%; % of naïve control mice ± SEM; n = 15). We
found a significant increase in the expression of D2R in PD
(P < 0.01, one-way ANOVA), but not PD-D (P > 0.05, one-way
ANOVA), mice when compared to naïve controls (Figures 4E,F;
PD mice, 123 ± 15%; PD-D mice, 112 ± 22%; % of naïve
control mice ± SEM; n = 15). These findings indicate that
dopamine depletion causes a significant increase in striatal D2R
expression, which is reversed by daily treatment with L-DOPA.
In addition, dopamine depletion and L-DOPA replacement cause
no significant changes in striatal expression of D1R and A2AR in
the dopamine-denervated striatum.
Dopaminergic Regulation of Striatal Levels
of PLA Signals for D1R-Gαolf
To examine the dopaminergic regulation of striatal levels of Gαolf
protein in close proximity to D1R protein, we used a sensitive
in situ PLA in sections prepared from 6-OHDA-lesioned striata
from PD and PD-D mice (Figure 5). In low-magnification
microscopic images, a marked and moderate increase in D1R-
Gαolf PLA signals was observed in the dorsal striatum in PD and
PD-D mice when compared to naïve controls (Figures 5A,B).
Higher-magnification microscopic images of the DL striatum
also show that compared to naïve controls (Figure 5C), there is
a marked and moderate increase in the D1R-Gαolf PLA signals
in 6-OHDA-lesioned striatal areas in PD (Figure 5D) and PD-D
(Figure 5E) mice. Quantitative densitometry analyses of the DL
striatum revealed increases of 92% (P< 0.001, one-wayANOVA)
and 50% (P < 0.001, one-way ANOVA) in the D1R-Gαolf PLA
signal in PD and PD-D mice, respectively, when compared
to naïve controls. There was a decrease of 42% (P < 0.001,
one-way ANOVA) in the D1R-Gαolf PLA signal in PD-D mice
when compared to PD mice (Figure 5F; PD mice, 192 ± 25%;
PD-D mice, 150 ± 21%; % of naïve control mice ± SEM;
n = 10). These findings indicate that dopamine depletion causes
a marked increase in striatal D1R-Gαolf PLA signal, which is
downregulated by daily treatment with L-DOPA. However, there
is a significant increase of striatal D1R-Gαolf PLA signal in PD-D
mice compared to naïve controls.
Dopaminergic Regulation of Striatal Levels
of PLA Signals for A2AR-Gαolf
To examine the dopaminergic regulation of striatal levels of Gαolf
protein in close proximity to A2AR protein, we used a sensitive
in situ PLA in sections prepared from 6-OHDA-lesioned striata
from PD and PD-D mice (Figure 6). Notably, low-magnification
microscopic images show an apparent decrease in the A2AR-
FIGURE 5 | Dopaminergic regulation of striatal levels of Gαolf proteins in close proximity to D1R proteins. Dual-antigen recognition in situ PLA used to
detect Gαolf proteins in proximity to D1R proteins (D1R-Gαolf) was carried out on normal hemispheres of naïve controls and on lesioned hemispheres from
6-OHDA-lesioned mice treated with daily injections of benserazide alone for 10 days (PD model) and from 6-OHDA-lesioned mice that received daily injections of
benserazide and L-DOPA for 10 days and exhibited dyskinesia (PD-D model). (A,B) Representative photomicrographs of striatal expression of D1R-Gαolf PLA signals
in normal and lesioned hemispheres from PD and PD-D mice (A), and their graded color-converted images (B). (C–E) Representative photomicrographs of the DL
striatum stained with the in situ PLA for D1R-Gαolf from naïve control (C), PD (D) and PD-D (E) mice. Their higher-magnification images are also shown in the insets
in (C–E). (F) Optical density quantification of D1R-Gαolf PLA signals in the DL striatum from PD (n = 10) and PD-D (n = 10) mice. Data are expressed as percentage
of naïve control mice (n = 10) and are means ± SEM. ∗∗∗P < 0.001 vs. normal controls; ###P < 0.001 vs. PD; one-way ANOVA (F(2,27) = 107.2) followed by
Bonferroni’s test. Scale bars: (A,B) = 2 mm; (C–E) = 25 µm; insets in (C–E) = 10 µm.
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 February 2017 | Volume 11 | Article 26
Morigaki et al. Striatal Gαolf Levels in L-DOPA-Induced Dyskinesia
Gαolf PLA signal in the DL striatum of PD-D mice when
compared to both naïve control and PD mice (Figures 6A,B).
Higher-magnification images also show the localization patterns
of A2AR-Gαolf PLA signals in the DL striatum of naïve control
(Figure 6C), PD (Figure 6D), and PD-D (Figure 6E) mice.
Quantitative densitometry analyses of the DL striatum revealed
decreases of 41% (P < 0.001, one-way ANOVA) and 45%
(P < 0.001, one-way ANOVA) in A2AR-Gαolf PLA signal
levels in PD-D mice, when compared to naïve controls and
PD mice, respectively (Figure 6F; PD mice, 104 ± 24%;
PD-D mice, 59 ± 21%; % of naïve control mice ± SEM;
n = 10). These findings indicate that L-DOPA replacement,
but not dopamine depletion, causes a significant decrease in
the striatal A2AR-Gαolf PLA signal in the dopamine-denervated
striatum.
Differences in Striatal Responsiveness to
Dopamine Stimulation between PD and
PD-D Mice
To assess changes in striatal responsiveness to dopamine
stimulation in PD and PD-D mice, we performed IHC using
an antibody against c-Fos, which is known to be induced in
the striatum and globus pallidus following the stimulation of
D1Rs and D2Rs (Marshall et al., 1993; LaHoste and Marshall,
1994). We prepared striatal sections from PD and PD-D
mice that received injections of L-DOPA (20 mg/kg) and
benserazide-HCl (12 mg/kg) 2 h before sacrifice on day 11
(see Figure 1A). Microscopic images of the DL striatum
stained for c-Fos from naïve control, PD and PD-D mice
are shown in Figure 7A. Compared to naïve controls that
also received the injections of L-DOPA (20 mg/kg) and
benserazide-HCl (12 mg/kg) 2 h before sacrifice, we found
a marked increase in the densities of c-Fos-positive (c-Fos+)
nuclei in the 6-OHDA-lesioned striatum in both PD and
PD-D mice. Quantitative densitometry analyses also showed
a marked increase (P < 0.001, two-way ANOVA) in the
density of c-Fos+ nuclei in the 6-OHDA-lesioned striatum in
both PD and PD-D mice when compared to naïve controls.
However, there was a decrease of ∼40% (P < 0.001, two-way
ANOVA) in the density of c-Fos+ nuclei in the 6-OHDA-
lesioned striatum of PD-D mice when compared to PD mice
(Figure 7B; naïve controls: 20 ± 12; PD mice: non-lesion,
31 ± 10 and 6-OHDA-lesion, 475 ± 55; PD-D mice: non-lesion,
FIGURE 6 | Dopaminergic regulation of striatal levels of Gαolf proteins in close proximity to A2AR proteins. Dual-antigen recognition in situ PLA used to
detect Gαolf proteins in proximity to A2AR proteins (A2AR-Gαolf) was carried out on normal hemispheres of naïve controls and on lesioned hemispheres from
6-OHDA-lesioned mice treated with daily injections of benserazide alone for 10 days (PD model) and from 6-OHDA-lesioned mice that received daily injections of
benserazide and L-DOPA for 10 days and exhibited dyskinesia (PD-D model). (A,B) Representative photomicrographs of striatal expression of A2AR-Gαolf PLA
signals in normal and lesioned hemispheres from PD and PD-D mice (A), and their graded color-converted images (B). (C–E) Representative photomicrographs of
the DL striatum stained with the in situ PLA for A2AR-Gαolf from naïve control (C), PD (D) and PD-D (E) mice. Their higher-magnification images are also shown in the
insets in (C–E). (F) Optical density quantification of A2AR-Gαolf PLA signals in the DL striatum from PD (n = 10) and PD-D (n = 10) mice. Data are expressed as
percentage of naïve control mice (n = 10) and are means ± SEM. ∗∗∗P < 0.001 vs. naive controls; ###P < 0.001 vs. PD; one-way ANOVA (F(2,27) = 72.6) followed by
Bonferroni’s test. Scale bars: (A,B) = 2 mm; (C–E) = 25 µm; insets in (C–E) = 10 µm.
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FIGURE 7 | Effects of dopamine stimulation on striatal and pallidal c-Fos expression in 6-OHDA-lesioned mice. An immunohistochemical study with
anti-c-Fos antibody was carried out on the striatal sections from PD and PD-D mice, which received injections of L-DOPA (20 mg/kg) and benserazide-HCl
(12 mg/kg) 2 h before sacrifice on day 11 (see Figure 1A), and those from naïve controls that also received the injections of L-DOPA (20 mg/kg) and
benserazide-HCl (12 mg/kg) 2 h before sacrifice. The density measurements were performed by counting the numbers of c-Fos-positive (c-Fos+) nuclei in a
0.5 mm × 0.5 mm field in the striatum and globus pallidus from each animal. (A) Representative photomicrographs of the DL striatum stained for c-Fos in naïve
control, PD and PD-D mice. The inset (red open box) in the naïve control is the corresponding figure from the atlas of Paxinos and Franklin (2001) to show the striatal
area that were analyzed in all naïve control, PD and PD-D mice. (B) Density quantification of c-Fos+ nuclei in the DL striatum from naïve controls (n = 10), and of
those on non-lesion and lesion sides in PD (n = 10) and PD-D (n = 10) mice. Data are expressed as means ± SEM. ∗∗∗P < 0.001 vs. naïve controls; ###P < 0.001 vs.
PD; two-way ANOVA (F(1,36) = 140.9) followed by Bonferroni’s test. (C) Representative photomicrographs of the globus pallidus stained for c-Fos in naïve control, PD
and PD-D mice. The inset (red open box) in the naïve control is the corresponding figure from the atlas of Paxinos and Franklin (2001) to show the pallidal area that
were analyzed in all naïve control, PD and PD-D mice. (D) Density quantification of c-Fos+ nuclei in the globus pallidus from naïve controls (n = 10), and of those on
non-lesion and lesion sides in PD (n = 10) and PD-D (n = 10) mice. Data are expressed as means ± SEM. ∗∗∗P < 0.001 vs. naïve controls; ##P < 0.01 vs. PD;
two-way ANOVA (F(1,36) = 80.8) followed by Bonferroni’s test. Scale bars: (A) = 200 µm; (C) = 100 µm.
29 ± 12 and 6-OHDA-lesion, 292 ± 49; means ± SEM;
n = 10). Microscopic images of the globus pallidus stained
for c-Fos obtained from naïve control, PD, and PD-D mice
are shown in Figure 7C. Compared to naïve controls, we
found increased densities of c-Fos+ nuclei in the globus
pallidus on the lesioned sides in both PD and PD-D mice.
Quantitative densitometry analyses also indicated a significant
increase (P < 0.001, two-way ANOVA) in the density of c-
Fos+ nuclei in the globus pallidus on the lesioned sides in
both PD and PD-D mice when compared to naïve controls.
Importantly, we found that there was an increase of ∼140%
(P < 0.01, two-way ANOVA) in the density of c-Fos+ nuclei
in the globus pallidus on the lesioned side in PD-D mice
when compared to PD mice (Figure 7D; naïve controls:
4 ± 2; PD mice: non-lesion, 5 ± 3 and 6-OHDA-lesion,
38 ± 8; PD-D mice: non-lesion, 8 ± 7 and 6-OHDA-lesion,
92 ± 11; means ± SEM; n = 10). These findings indicate
that dopamine depletion causes a marked increase in the
responsiveness of striatal D1-cells to dopamine stimulation,
which is downregulated by daily treatments with L-DOPA.
Given the changes in striatal D2R expression in PD and
PD-D mice (see above), it is likely that in the dopamine-
denervated striatum, dopamine depletion may cause increased
striatal D2R expression, which then enhances the responsiveness
of D2-cells to dopamine stimulation (Cai et al., 2002). Notably,
L-DOPA replacement could induce a further increase in the
responsiveness of D2-cells to dopamine stimulation despite no
obvious increase in striatal D2R expression in the dopamine-
denervated striatum.
DISCUSSION
Here we used IHC and in situ PLA to determine the region-
and cell-type- specific distributions of Gαolf proteins in the
mouse striatum. Using a mouse model of hemiparkinsonism
induced by 6-OHDA, we also found that daily pulsatile
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FIGURE 8 | Proposed diagram for dopaminergic regulation of Gαolf levels that determine responsiveness to dopamine stimulation in striatal D1- and
D2-cells. The heights of the red and blue columns indicate the abundance of Gαolf proteins in D1-cells and D2-cells, respectively. In PD mice, D1-cells might exhibit
the dopamine D1R hypersensitivity caused by a dramatic increase in their Gαolf levels, while D2-cells might show no apparent changes in their Gαolf levels. In PD-D
mice, D1-cells might show an increase in their Gαolf levels, while D2-cells might show a decrease in their Gαolf levels, which might result in an enhanced
responsiveness to D2R activation. Abbreviations: PD, Parkinson’s disease: PD-D, PD with dyskinesia; ACh, acetylcholine; D1-cell, dopamine D1 receptor-expressing
striatonigral medium spiny neuron; D2-cell, dopamine D2 receptor-expressing striatopallidal medium spiny neuron; D1R, dopamine D1 receptor; D2R, dopamine D2
receptor; Gαolf, olfactory type G-protein α subunit.
administration of L-DOPA might induce usage-dependent
changes in Gαolf expression not only in D1-cells, but also in
D2-cells in the dopamine-depleted striatum (see Figure 8).
This raises the possibility that LID might result from reduced
A2AR/Gαolf/cAMP signal levels in D2-cells, which may be caused
by intermittent and pulsatile activation of postsynaptic D1Rs in
the striatum. Our results support and provide new insights into
the hypothesis that LID is associated with a decrease in activity
of ‘‘indirect’’ striatopallidal pathway (Crossman, 1990; DeLong,
1990; Brotchie, 2005; Guridi et al., 2012).
Strategic Localization of Gαolf Proteins in
the Striatum
We used IHC to demonstrate that Gαolf IR is highly concentrated
in the DL striatum, which corresponds to the motor-sensory
territory in rodents and is analogous to the putamen in primates
(Graybiel, 2008). This implies that Gαolf may have a unique
position in regulating the activities of the cortico-thalamo-basal
ganglia circuit involved in motor functions, i.e., the motor
loop (Alexander and Crutcher, 1990), at the striatal level.
Although a previous study revealed no obvious compartmental
difference in Gαolf mRNA expression throughout striatal
development in rats (Sakagami et al., 1995), we observed
differential concentrations of Gαolf IR in the striosome and
matrix compartments, with higher densities of Gαolf IR in
the striosomes relative to the matrix. This finding suggests
that Gαolf may be a key molecule for controlling differential
responses of striosome-matrix systems to D1R activation in
adult mice. There is evidence that in experimental animal
models with 6-OHDA-lesions (Hervé et al., 1993; Corvol et al.,
2004; Alcacer et al., 2012; Ruiz-DeDiego et al., 2015) or in
those with a total absence of D1Rs due to D1R gene targeting
(Hervé et al., 2001), the upregulation of Gαolf levels in the
striatum is not accompanied by a parallel increase in Gαolf
mRNA expression. Thus, homeostatic regulation of striatal
Gαolf protein levels is thought to occur via post-translational
mechanisms, wherein the altered expression of Gαolf protein
depends directly on its rate of usage (Hervé, 2011). We
suggest that when compared to the matrix, the striosomes
might have the lower levels of D1R/Gαolf stimulation, which
may then lower the Gαolf degradation rate and lead to
accumulation of the protein. Our assumption is supported
by the present finding that changes in striatal Gαolf IR
expression were primarily found in the matrix in both PD and
PD-D mice.
In this study, we first used highly sensitive dual-antigen
recognition in situ PLA using a combination of the Brightfield
Duolink PLA kit reagents and the TSA system (see ‘‘Materials
and Methods’’ Section). This dual-antigen recognition PLA
technique allowed us to obtain specific and efficient fluorescent
signals showing Gαolf protein in close proximity to D1R or
A2AR protein in the striatum. However, we cannot say that
all the PLA signals detected here resulted from the direct
interaction (or actual coupling) of Gαolf protein with D1R or
A2AR protein. Borroto-Escuela et al. (2013) have shown that
PLA can indicate a close proximity between two proteins,
which is not always a reflection of direct interaction. This is
because in situ PLA signals can be detected when two protein
epitopes are in close proximity with ranges of 10–30 nm or
more. In addition, although the precise mechanisms by which
Gαolf protein interact with D1R or A2AR protein remains
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unclear, it was also noted that in striatal membrane, the
content in Gαolf protein would be almost one to two orders
of magnitude higher than that in D1R or A2AR (Hervé,
2011).
Striatal Gαolf as a Determinant of the
Increased Responsiveness of D1-cells to
Dopamine Stimulation in LID
As shown in previous studies (Alcacer et al., 2012; Ruiz-DeDiego
et al., 2015), we found a marked increase in striatal Gαolf protein
levels in PD mice with 6-OHDA lesions. This is in line with
evidence that dopamine depletion may lead to up-regulation
of Gαolf protein expression in the rat striatum (Hervé et al.,
1993; Marcotte et al., 1994; Penit-Soria et al., 1997; Corvol et al.,
2004; Rangel-Barajas et al., 2011) and in the putamen in patients
with PD (Corvol et al., 2004). Given the evidence that striatal
levels of D1R (Shinotoh et al., 1993; Turjanski et al., 1997:
Hurley et al., 2001) and other major mediators of D1R signaling
(Girault et al., 1989; Nishino et al., 1993) are unchanged in
PD patients, the dramatic increase in striatal Gαolf protein level
may be a key event in the D1R hypersensitivity that develops
in PD (Alcacer et al., 2012). In support of this notion, we
detected no obvious changes in striatal D1R expression in PD
mice.
Previous data have suggested that the up-regulation of
Gαolf protein levels in the dopamine-depleted striatum is
post-translational (Hervé et al., 1993; Ruiz-DeDiego et al., 2015)
and results from the disuse of the D1Rs (Hervé et al., 2001).
Indeed, daily administration of L-DOPA for 10 days resulted
in a down-regulation of the increased Gαolf protein levels in
the 6-OHDA-lesioned striatum in PD-D mice. However, we
also found a significant increase in striatal Gαolf levels in PD-D
mice when compared to naïve controls. In agreement with the
changes in striatal Gαolf levels in PD and PD-D mice, in situ
PLA also revealed that striatal D1R-Gαolf PLA signals were
dramatically increased in PD mice and moderately increased in
PD-D mice. These findings imply an increased responsiveness
of D1-cells to D1R activation in PD-D mice, although this
responsiveness is lower than that found in PD mice. Our
assumption is also supported by the fact that, compared to naïve
controls, a significant increase in the number of striatal c-Fos+
nuclei consequent to L-DOPA administration was evident in
PD-D mice, although this increase was more pronounced in
PD mice. Since Gαolf represents the rate-limiting factor in D1R-
mediated cAMP production in D1-cells, these findings suggest
that striatal Gαolf level acts as a determinant for the increased
responsiveness of D1-cells to dopamine stimulation in LID (see
Figure 8).
Striatal Gαolf as a Determinant of the
Increased Responsiveness of D2-cells to
Dopamine Stimulation in LID
It has been postulated that repeated exposure to dopaminergic
agents leads to increased sensitivity of D2-cells to D2R
activation in the dopamine-depleted striatum in experimental
animals (Engber et al., 1989; Asin et al., 1995; Kashihara
et al., 2000). However, no obvious increase in striatal D2R
expression has been observed in PD patients treated with
dopaminergic drugs (Rinne et al., 1981; Guttman and
Seeman, 1985; Antonini et al., 1997; Thobois et al., 2004).
In agreement with this notion, we found that pallidal
c-Fos induction consequent to L-DOPA administration
was more marked in PD-D mice compared to PD mice.
On the other hand, there was increased expression of
striatal D2Rs in PD mice, but not in PD-D mice. This
indicates that the repeated administration of L-DOPA
results in an increased responsiveness of D2-cells to striatal
D2R activation in the dopamine-denervated striatum, and
suggests that this phenomenon might underlie LID. Using
an in situ PLA, we found that A2AR-Gαolf PLA signals
were markedly reduced along with Gαolf protein levels in
the 6-OHDA-lesioned striatum of PD-D mice. This novel
finding indicates that as in D1-cells, repeated exposure to
L-DOPA causes down-regulation of Gαolf protein levels in
D2-cells in the dopamine-depleted striatum. This then leads
to the facilitation of the effects of dopamine on D2-cells by
reducing A2AR/Gαolf signaling-mediated cAMP production
(see Figure 8). This may be the reason that PD-D mice
display an increased responsiveness of D2-cells to dopamine
stimulation. However, the mechanism by which repeated and
pulsatile injections of L-DOPA causes a decrease in A2AR/Gαolf
PLA signals in PD-D remains a matter of speculation, as
follows.
A2AR usage by endogenous adenosine results in a basal rate
of Gαolf degradation (Hervé et al., 2001). It has been shown
that in experimental animals with 6-OHDA-lesions, chronic (or
persistent) dopamine depletion caused no significant changes
(Ballarin et al., 1987; Herrera-Marschitz et al., 1994; Nomoto
et al., 2000) or slight decrease (Pinna et al., 2002) in the
extracellular adenosine levels in the striatum. In accordance with
these findings, our present results also showed no significant
changes in striatal levels of A2AR-Gαolf PLA signals in PD mice.
Thus, we suggest that chronic dopamine depletion per se might
cause no obvious changes in A2AR/Gαolf signaling activities
that depend on the endogenous adenosine levels in striatal
D2-cells. However, it is known that endogenous levels of
adenosine are increased in response to the activation of N-
methyl-D-aspartate (NMDA) receptors (Delaney and Geiger,
1998; Delaney et al., 1998), which can be facilitated by
D1R stimulation (Cepeda and Levine, 2012; Morigaki and
Goto, 2015), in the striatum. A landmark report has shown
that in the rat striatum, transient (pulsatile) stimulation of
D1Rs facilitates the NMDA receptor-dependent increase in
extracellular adenosine levels (Harvey and Lacey, 1997). These
findings suggest that in 6-OHDA-lesioned mice with D1R
hypersensitivity, repeated exposure to L-DOPA may lead to
a transient activation of D1Rs, which then enhances the
NMDA receptor-dependent increase in adenosine release in the
dopamine-denervated striatum. Moreover, Nash and Brotchie
(2000) have shown that in striatal slices prepared from rats
with 6-OHDA lesions, NMDA receptor activation could cause
a marked increase in adenosine release and, thereby, indirectly
stimulate A2ARs. Taken together, we speculate that in the
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6-OHDA-lesioned striatum of PD-D mice, decreased Gαolf
levels in D2-cells might be due to increased extracellular
adenosine levels caused by the daily pulsatile activation of
striatal D1Rs. If our assumption is correct, striatal D1R signals
might contribute to regulation of the Gαolf protein levels in
not only D1-cells but also D2-cells in the dopamine-depleted
striatum.
Because adenosine/A2AR signaling functionally opposes
the actions of D2Rs on D2-cells by its ability to increase
the A2AR/Gαolf-dependent cAMP production, it has so
far been suggested that A2AR antagonism may boost the
anti-parkinsonian action of D2R agonists in treating PD
symptoms (Jenner, 2003; Schwarzschild et al., 2006; Fuxe
et al., 2007; Huot et al., 2013). In addition, based on the
evidence that striatal A2AR expression might be increased in PD
patients with dyskinesia (Calon et al., 2004; Ramlackhansingh
et al., 2011) and in dyskinetic animal models of PD (Jenner
et al., 2009), it has also been suggested that adenosine
A2A sites might be a potential pharmacologic target for
reducing LIDs (Jenner et al., 2009; Ramlackhansingh et al.,
2011; Huot et al., 2013; Kanda and Uchida, 2014). In
Japan, istradefylline, an A2AR antagonist, is currently used
in clinics for treating PD patients (Kondo and Mizuno,
2015). The drug has shown to improve ‘‘off’’ time in
patients with advanced PD, but has not shown anti-LID
effects in the absence of a reduction in dopaminergic drug
dosage. Adjunct use of istradefylline often causes dyskinetic
symptoms as a major adverse effect (Kondo and Mizuno,
2015). Considering usage-dependent Gαolf degradation
through adenosine/A2AR, we assume that in PD patients
treated with L-DOPA, adenosine/A2AR antagonism might
be effective in reducing the ‘‘priming’’ of LID. However,
once LID is established, adenosine/A2AR antagonism might
exacerbate dyskinetic symptoms. Our assumption may
corroborate the notion that A2AR activation might be
required for dyskinesia ‘‘priming’’ mechanism (Brotchie,
2005).
CONCLUSION
Because Gαolf protein level serves as a determinant of cAMP
signal-dependent activity in both D1-cells and D2-cells in
the striatum, Gαolf may represent an ideal target for the
modulation of striatal functions under physiological and
pathological conditions. Dysregulation of Gαolf expression has
been associated with the pathophysiology of several brain
disorders (Hervé, 2011). Of our particular interest is that the
GNAL gene, which encodes Gαolf, is a causative gene in primary
(torsion) dystonia (Fuchs et al., 2013). This is direct evidence
that Gαolf plays a pivotal role in the ‘‘motor loop’’ of the
cortico-basal ganglia circuits. Under parkinsonian conditions,
dopamine depletion results in a crucial D1R hypersensitivity in
the striatum, which leads to the beneficial effects of L-DOPA
in PD patients, but also generates LID. In this study, we found
that in the 6-OHDA-lesioned striatum of PDmice, daily pulsatile
administrations of L-DOPA may cause usage-induced changes
in striatal Gαolf levels, leading to increased responsiveness to
dopamine stimulation in both D1-cells and D2-cells. Thus
we suggest that L-DOPA-induced changes in Gαolf levels in
the dopamine-depleted striatum may be a key event in LID
development.
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